Efficacy and Safety of Intralesional Vitamin D3 in Treatment of Viral Warts: A Systematic Review and Meta-analysis
Journal of Dermatology and Dermatologic Surgery · 2025-07 · 29 (2) · 77-88
DOI: 10.4103/jdds.jdds_35_24 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Dermatology and Dermatologic Surgery, online erschienen am 09.04.2026. Verfasst von Ahmad A. El-Ebiary und 1 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Intralesional Vitamin D3 has recently demonstrated encouraging outcomes in the treatment of various wart types.
Purpose
This study evaluated the efficacy and safety of intralesional Vitamin D3 in the treatment of viral warts.
Methods
We included randomized controlled trials that reported the efficacy of intralesional Vitamin D3 in the treatment of warts.
Results
Twenty-eight studies with a total of 1983 patients were included. For all types of warts, intralesional Vitamin D3 was more effective than placebo (risk ratio [RR] = 6.44; 95% confidence interval [CI]: 2.58–16.10, P < 0.0001), Candida antigen (Ag) (RR = 1.14; 95% CI: 0.76–1.71, P = 0.54), and cryotherapy (RR = 1.52; 95% CI: 1.18–1.95, P = 0.01) in achieving complete clearance of warts at site of injection. Vitamin D3 was less effective than purified protein derivative (PPD) (RR = 0.90; 95% CI: 0.76–1.05, P = 0.18), measles, mumps, and rubella (MMR) (RR = 0.89; 95% CI: 0.76–1.05, P = 0.18), and Bacillus Calmette–Guérin (BCG) (RR = 0.69; 95% CI: 0.53–0.90, P = 0.005). In patients with plantar warts, intralesional Vitamin D3 was more effective than Candida Ag (RR = 1.44; 95% CI: 0.87–2.36, P = 0.15), zinc sulfate 2% (RR = 1.20; 95% CI: 0.81–1.77, P = 0.36), and placebo (RR = 4.87; 95% CI: 1.43–16.63, P = 0.01). For common warts, Vitamin D3 was more effective than placebo (RR = 8.25; 95% CI: 1.65–41.29, P = 0.01). Vitamin D3 also cleared more distant warts than did placebo (RR = 11.83; 95% CI: 3.39–41.26, P = 0.0001) and zinc sulfate 2% (RR = 2.50; 95% CI: 0.06–105.62, P = 0.63). Efficacy of Vitamin D3 in achieving complete cure at distant sites was lower than for Candida Ag (RR = 0.56; 95% CI: 0.20–1.57, P = 0.27) and PPD (RR = 0.93; 95% CI: 0.69–1.25, P = 0.63). Most of the adverse effects associated with Vitamin D3 were not severe. Vitamin D3 had lower recurrences than Candida Ag, MMR, zinc sulfate 2%, and placebo, while PPD showed better results than Vitamin D3.
Conclusion
Intralesional Vitamin D3 is an effective and tolerable immunotherapeutic agent for wart treatment.
Zitieren
APA
El-Ebiary, A. A., & Alsaati, A. A. (2025). Efficacy and Safety of Intralesional Vitamin D3 in Treatment of Viral Warts: A Systematic Review and Meta-analysis. Journal of Dermatology and Dermatologic Surgery, 29(2), 77-88. https://doi.org/10.4103/jdds.jdds_35_24
Vancouver
El-Ebiary AA, Alsaati AA. Efficacy and Safety of Intralesional Vitamin D3 in Treatment of Viral Warts: A Systematic Review and Meta-analysis. Journal of Dermatology and Dermatologic Surgery. 2025;29(2):77-88. doi:10.4103/jdds.jdds_35_24
BibTeX
@article{ElEbiary2025,
author = {El-Ebiary, Ahmad A. and Alsaati, Ahmed A.},
title = {Efficacy and Safety of Intralesional Vitamin D3 in Treatment of Viral Warts: A Systematic Review and Meta-analysis},
journal = {Journal of Dermatology and Dermatologic Surgery},
year = {2025},
volume = {29},
number = {2},
pages = {77--88},
doi = {10.4103/jdds.jdds_35_24}
}
EUVIMED